Partnering opportunity

Chemokine for the therapeutic treatment of medulloblastoma


An Italian research team has developed a novel therapeutic agent for treating medulloblastoma, one of the most widespread paediatric brain tumours. The new therapeutic agent is the Cxcl3 chemokine (C-X-C motif, ligand 3). The researchers are looking for partners interested in financial agreements and/or technical cooperation agreements.

Partner expertise sought

The partner sought is an investor, i.e. a business angel, interested in covering the patent costs and in supporting financially the research programme for favoring technological transfer (Financial agreement). The researchers is also looking for other research institutes/universities and/or pharmaceutical and biotech companies to reach technical cooperation agreements for sharing resources and skills, proceed with the clinical studies on humans, and develop pharmaceutical solutions.


An Italian research group has developed a novel therapeutic agent for treating medulloblastoma. Medulloblastoma is one of the most widespread paediatric brain tumours, principally caused by the prolonged mitotic activity of glioma-propagating cells (GCPs) inside the external granular layer (EGL) of the cerebellum, making them potential targets of transforming insults, resulting in gene mutation and tumorigenesis. The Italian researchers have recently shown that it is sufficient to delay the migration of the GCPs from the EGL, forcing them to proliferate for a longer period, to enhance the frequency of the transformation of the GCPs into a neoplastic cell. The researches demonstrated this in a new mouse model, generated by crossing mice of a spontaneous medulloblastoma line (Patched1 heterozygous, which have hyperactivation of the Shh pathway) with the mouse lacking the medulloblastoma tumor-suppressor gene (Tis21); the resulting mice (Tis21-/-/Patched1+/-) show a dramatic increase of medulloblastoma frequency, with respect to the Patched1 heterozygous mice model. Remarkably, in Tis21-/-/Patched1+/- mice they observed not only increase of the frequency of medulloblastoma, but also an increase of the tumor lesions at the surface of cerebellum. This phenotype is surprisingly not associated to increase of proliferation of GCPs, but rather to a strong decrease of the migration of GCPs from the surface of cerebellum toward the internal layers of cerebellum. In particular, they identified, by a genome-wide analysis, the chemokine Cxcl3 as a new responsible for the migration of GCPs. In neoplastic GCPs, Cxcl3 is reduced causing a huge increase of the frequency of medulloblastomas in consequence of the reduced migration of GCPs from the surface of cerebellum. Importantly, they have also shown that the treatment of cerebellar slices with Cxcl3 reduces the extension of diffused medulloblastoma lesions. Therefore, ClCx3 is suggested as a novel therapeutic agent for treating medulloblastoma. The Italian group is looking for new partners for Financial support to improve R&D and cover the patent costs (i.e. business angels). Furthermore the researchers are also interested in Technical cooperation agreement for sharing resources and skills; i.e. the researchers would like to cooperate with universities, pharmaceutical and biotech companies to proceed with the clinical studies on human and development of pharmaceutical formulations.

Advantages and innovations

The Italian group has performed in vivo tests on mice. The intracerebellar Cxcl3 administration with Alzet pumps for one month induced the disappearance of medulloblastoma in heterozygous Patched1 mice (which develop spontaneous medulloblastoma). The result confirms the inactivation mechanism of cancer cells through an induction of migration outside the proliferative zone, which forces them to differentiate and terminate the cancer program. An additional series of experiments is currently being performed: a) Expression of Cxcl3 receptor in various types of medulloblastoma (in humans); b) Cxcl3 levels in cerebrospinal fluid. Therefore, Cxcl3 could be inserted into a clinical trial in a man (not a child) with recurrences.

Development stage

Field tested/evaluated

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

What next?

To finish up, we just need some extra details about you and your company